Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for F-star Therapeutics, Inc. (FSTX)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | Benzinga
3 days ago | GlobeNewsWire
5 days ago | Zacks Investment Research
a week ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | Business Wire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
About:
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
75Address:
F-star Therapeutics, Inc. Eddeva B920 Babraham Research Campus Cambridge CB22 3AT United KingdomWebsite:
Home